enGene Therapeutics Inc. Common Stock Status update
Review the key takeaways and the transcript of this earnings call.
- enGene Therapeutics discussed the Non-muscle invasive bladder cancer (NMIBC) market and their product candidate, Dental Imaging, a novel non-viral gene therapy administered intravesically to the bladder.
- Dental Imaging is currently in a phase two Legend trial with cohorts including high risk BCG unresponsive NMIBC patients with carcinoma in situ or papillary only disease.
- Interim data showed a 54% complete response rate at any time without surfactant, with 55% of patients experiencing mostly mild treatment-related adverse events.
- The company completed FDA validation batches and plans to meet with the FDA and initiate a BLA filing by the end of the year, aiming for potential approval in 2027.
- Market research indicated the addressable BCG unresponsive population is larger than previously believed, with sequencing through multiple therapies before radical cystectomy becoming common.
- Community urology practices vary in resources and preferences, with Dental Imaging's profile potentially well suited for resource-limited, workflow-constrained, and economic-focused practices.
- Pricing benchmarks for NMIBC therapies have increased to about $690,000 annually, with payers indicating coverage at parity assuming NCCN guideline category 2A or higher.
- Dr. Neil Shaw emphasized the importance of bladder preservation, the evolving treatment landscape with multiple therapies, and the need for therapies with manageable logistical, personnel, and time toxicities for community practices.
- Dr. Shaw noted that sequencing of 3 to 4 therapies before cystectomy is common and that payer pushback on sequencing has not been observed.
- Q&A revealed that Dental Imaging is expected to fit into various lines of therapy, with community physicians valuing efficacy, tolerability, convenience, and economics in treatment decisions.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good morning, and welcome to the enGene Therapeutics call to discuss the non-muscle invasive bladder cancer market. At this time, all attendees are in a listen-only mode, and a question and answer session will follow the formal presentation. As a reminder, this call is being recorded, and a replay will be made available on the enGene website following the conclusion of the event. I'd now like to turn the call over to Lauren Hopfer, Executive Director of Investor Relations at enGene Therapeutics. Please go ahead, Lauren. Thank you.
Good morning, everyone, and thank you for joining our call to discuss new insights to the non-muscle invasive bladder cancer market. Joining me on the call this morning are Ron Cooper, our Chief Executive Officer, Amy Pott, our Chief Global Commercialization Officer, and we're pleased to welcome Dr. Neal Shore, Medical Director for the START Cancer Research. Before we begin, I would like to remind you that during our prepared remarks and Q&A session to follow, we may make forward-looking statements for purposes of U.S. and Canadian securities laws.
These statements include, but are not limited to, our current expectations regarding the potential benefits of detalimogene, the efficacy, safety, and product profile of detalimogene, timing of clinical data, timing of regulatory submission, prospects for regulatory approval of detalimogene, projections of market opportunity and market share, the anticipated market acceptance of detalimogene if approved, our current views and market research on the non-muscle invasive bladder cancer market, implications or takeaways from our market research, estimates, projections, or forecasts of payer coverage of therapies, our expectations regarding how healthcare providers may use detalimogene, or sequencing of products. They involve risks, uncertainties, and assumptions that are difficult to predict and may not prove to be accurate. Results may vary. These statements should be considered only in conjunction with the information in our filings made with Canadian and American securities regulators, including our Risk Factors section of our annual report on Form 10-K.
At this time, I will turn the call over to Ron Cooper, enGene's President and CEO.
Ron? Great. Thanks, Lauren. Thank you all for joining us this morning.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring